Brief · Use case · Corporate Development
Viral Vector CDMO Landscape.
LiveLandscapeGive the board a view of viral vector CDMOs: capacity and size by source, who plays where and what it means for a manufacturing decision.
Viral Vector CDMO Landscape is a ready-made use case for Corporate Development. It ships under the Landscape template.
For corporate development and manufacturing leads. You get the picture in brief, the boundary and inclusion rule, estimates side by side, providers by segment and the implications for your plan. Figures are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
What is the landscape of contract development and manufacturing organizations for viral vector gene therapies, for a developer deciding where to place late-stage manufacturing?
What is mapped
The market is defined by what a manufacturer can make and under which rules. The landscape starts from the regulatory frame and then lists the organizations that meet its inclusion rule.
| Segment or source | What it holds | What the landscape does with it |
|---|---|---|
| The demand side | FDA’s list of licensed cellular and gene therapy products, current as of 17 September 2026, holds about 54 products, among them CAR-T therapies, gene therapies and cord blood products. It shows how many products have reached the market and who makes them.1 | FDA’s page of approved cellular and gene therapy products. |
| What manufacturers must show | FDA’s January 2020 guidance recommends the chemistry, manufacturing and control information that sponsors should include in an application for a human gene therapy, so that safety, identity, quality, purity and strength can be assured.2 | FDA’s CMC guidance for human gene therapy INDs. |
| Capacity and capability | Which organizations offer viral vector manufacturing at late-stage scale, by vector type, and what each states about capacity. | Company disclosures, listed companies’ filings and site descriptions; capacity claims are marked as company statements. |
What the landscape does
Demand, from a public record. FDA’s page lists the licensed products and their manufacturers, so the landscape can show who already manufactures commercially. It uses that as a check on any organization’s claim to late-stage experience.1
Quality is the regulator’s question. A developer choosing where to place late-stage manufacturing must show regulators the chemistry, manufacturing and controls of the product. The landscape lists the content FDA recommends and says what a manufacturer needs to be able to provide.2
Capacity claims are claims. Statements about capacity and timelines come from the organizations themselves. The landscape labels them as such and does not turn them into a ranking.
What is shaping it. At Comprehensive length the landscape names the forces: the number of products moving toward approval, capacity constraints, regulatory expectations and the entry of in-house manufacturing.1,2
Recommended length
Comprehensive
The forces behind the market matter to the decision. Comprehensive adds the section on what is shaping it.
You can pick another length on the form. The other two stay available.
Assumptions the landscape checks
The landscape states the assumptions its boundary and its sizes rest on, and says what each gap limits. Examples for this market:
- FDA’s list of licensed products reflects the commercial demand relevant to the developer.
- An organization’s published description of its capacity is accurate and current.
- The guidance cited is the current version.
Standards, guidance and sources
Regulatory frame
The decision practice behind the memo itself is on the template page.
What gets flagged
Any capacity claim that rests on the organization’s own statement, any manufacturer that cannot be matched to a licensed product, and any vector type outside the boundary.
What arrives
- The picture in brief
- Scope and boundary
- The market in numbers
- Who plays where
- What is shaping it
- What it means for us
- What we could not source
What it will not do
It does not rank players or give a single market size. It shows estimates side by side with their sources, and a position on a map is labeled analyst judgment.
It is not an audit or a quality assessment of any manufacturer, and it does not recommend a site.
It does not give a single market size when the sources disagree. It shows each estimate and says why they differ.
It does not rank players. A map places them on defined axes and labels the placement as judgment.
It is a snapshot of one date, from public sources. A player it could not find is listed as a gap.
References
- [1] U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 17 September 2026. Read on 9 October 2026.
- [2] U.S. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Guidance for industry, January 2020. Status and scope as given in FDA’s listings found by search; the guidance text was not read.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.